AR089122A1 - Formulaciones orales para tratar la sobrecarga de metales - Google Patents
Formulaciones orales para tratar la sobrecarga de metalesInfo
- Publication number
- AR089122A1 AR089122A1 ARP120104611A ARP120104611A AR089122A1 AR 089122 A1 AR089122 A1 AR 089122A1 AR P120104611 A ARP120104611 A AR P120104611A AR P120104611 A ARP120104611 A AR P120104611A AR 089122 A1 AR089122 A1 AR 089122A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- integer
- hydrogen
- independently selected
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones orales eficaces basadas en análogos de desazadesferritiocin-poliéter (DADFT-PE), sus sales y polimorfos, así como también su aplicación para el tratamiento de la sobrecarga de metal, en particular, la sobrecarga férrica, y enfermedades, trastornos y afecciones asociados. Reivindicación 1: Una formulación oral que comprende un compuesto de fórmula (1) en una cantidad eficaz para tratar la sobrecarga de metal y un excipiente farmacéuticamente aceptable, donde: R¹, R², R³, R⁴, y R⁵ se seleccionan independientemente entre hidrógeno, hidroxi, alquilo, arilalquilo, alcoxi, y CH₃O((CH₂)ₙ-O)ₘ-, cualquiera de los cuales puede estar opcionalmente sustituido; R⁶, R⁷, y R⁸ se seleccionan independientemente entre hidrógeno, halógeno, hidroxi, alquilo inferior, y alcoxi inferior; m es un número entero de 0 a 8; y n es un número entero de 0 a 8; o su sal o polimorfo. Reivindicación 38: Una forma de dosificación sólida que comprende un compuesto de fórmula (1) y un excipiente farmacéuticamente aceptable, donde la forma de dosificación sólida se caracteriza por una velocidad de disolución que da como resultado más del 50% del compuesto de fórmula (1) se disuelve en solución dentro de los 30 minutos en un ensayo de disolución conducido según un protocolo estándar de la USP, la Farmacopea Europea o la Farmacopea Británica; donde: R¹, R², R³, R⁴, y R⁵ se seleccionan independientemente entre hidrógeno, hidroxi, alquilo, arilalquilo, alcoxi, y CH₃O((CH₂)ₙ-O)ₘ-, cualquiera de los cuales puede estar opcionalmente sustituido; R⁶, R⁷, y R⁸ se seleccionan independientemente entre hidrógeno, halógeno, hidroxi, alquilo inferior, y alcoxi inferior; m es un número entero de 0 a 8; y n es un número entero de 0 a 8; o su sal o polimorfo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161568914P | 2011-12-09 | 2011-12-09 | |
US201161568890P | 2011-12-09 | 2011-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089122A1 true AR089122A1 (es) | 2014-07-30 |
Family
ID=48574916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104611A AR089122A1 (es) | 2011-12-09 | 2012-12-07 | Formulaciones orales para tratar la sobrecarga de metales |
Country Status (9)
Country | Link |
---|---|
US (1) | US8993606B2 (es) |
EP (1) | EP2787994A4 (es) |
JP (1) | JP2015500294A (es) |
AR (1) | AR089122A1 (es) |
AU (1) | AU2012347595A1 (es) |
BR (1) | BR112014013985A2 (es) |
CA (1) | CA2857990A1 (es) |
TW (1) | TW201338777A (es) |
WO (1) | WO2013086312A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2761200T3 (es) | 2011-12-16 | 2020-05-19 | Univ Florida | Usos de análogos de 4'-desferritiocina |
WO2014143630A1 (en) | 2013-03-15 | 2014-09-18 | Ferrokin Biosciences, Inc. | Polymorph forms of desazadesferrithiocin analogs |
AU2014352780A1 (en) * | 2013-11-22 | 2016-06-09 | University Of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
CA2984250A1 (en) | 2015-04-27 | 2016-11-03 | University Of Florida Research Foundation, Incorporated | Metabolically programmed metal chelators and uses thereof |
WO2018104130A1 (en) | 2016-12-07 | 2018-06-14 | Lumileds Holding B.V. | Flash light emitter with remote communication function |
JP7554253B2 (ja) | 2019-07-19 | 2024-09-19 | ヴィフォール (インターナショナル) アクチェンゲゼルシャフト | 輸血依存性β-サラセミア(TDT)の治療で使用するためのフェロポーチン阻害剤 |
JP2024504349A (ja) | 2021-01-20 | 2024-01-31 | ビフォー (インターナショナル) エージー | 骨髄異形成症候群(mds)の処置において使用するためのフェロポーチン阻害剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2732625T3 (es) | 2005-04-04 | 2019-11-25 | Univ Florida | Análogos de poliéter de desferritiocina |
US8067451B2 (en) * | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
CA2680592C (en) | 2007-03-15 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues and uses thereof in treating pathological conditions |
CN103435569B (zh) * | 2008-07-14 | 2015-08-19 | 法罗肯生物科学公司 | 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物 |
BR112012001761A2 (pt) | 2009-07-27 | 2017-05-09 | Ferrokin Bioscience Inc | composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo |
JP5925679B2 (ja) | 2009-08-25 | 2016-05-25 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | デスフェリチオシンポリエーテル類似体およびその使用 |
US9045440B2 (en) | 2010-05-04 | 2015-06-02 | Ferrokin Biosciences, Inc. | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents |
-
2012
- 2012-12-07 AU AU2012347595A patent/AU2012347595A1/en not_active Abandoned
- 2012-12-07 TW TW101146269A patent/TW201338777A/zh unknown
- 2012-12-07 BR BR112014013985A patent/BR112014013985A2/pt not_active IP Right Cessation
- 2012-12-07 AR ARP120104611A patent/AR089122A1/es not_active Application Discontinuation
- 2012-12-07 EP EP12856135.4A patent/EP2787994A4/en not_active Withdrawn
- 2012-12-07 JP JP2014546115A patent/JP2015500294A/ja active Pending
- 2012-12-07 CA CA2857990A patent/CA2857990A1/en not_active Abandoned
- 2012-12-07 WO PCT/US2012/068432 patent/WO2013086312A1/en active Application Filing
- 2012-12-07 US US13/708,087 patent/US8993606B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2787994A1 (en) | 2014-10-15 |
EP2787994A4 (en) | 2015-08-26 |
US20130225645A1 (en) | 2013-08-29 |
US8993606B2 (en) | 2015-03-31 |
JP2015500294A (ja) | 2015-01-05 |
BR112014013985A2 (pt) | 2017-06-13 |
AU2012347595A1 (en) | 2014-06-26 |
TW201338777A (zh) | 2013-10-01 |
CA2857990A1 (en) | 2013-06-13 |
WO2013086312A1 (en) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales | |
CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
CO2018013717A2 (es) | Piridinas sustituidas como inhibidores de dnmt1 | |
CO6470847A2 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
BR112016000909A8 (pt) | derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas | |
UY33606A (es) | DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC | |
BR112015000106A2 (pt) | moduladores heterocíclicos de síntes de lipídio | |
NI201100158A (es) | Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona | |
DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
PE20221914A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
CO6541528A2 (es) | Derivados de la cromenona | |
UY32582A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero | |
CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
UY36123A (es) | Derivados de carboxamida | |
CU20190042A7 (es) | Compuestos derivados de naftiridinona | |
AR120158A2 (es) | Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue | |
EA201891027A1 (ru) | Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение | |
AR111416A2 (es) | Compuesto terapéutico para el dolor y síntesis del compuesto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |